European, Phase 3, Open-Label, Single-Arm, Single-Dose Gene Replacement Therapy Clinical Trial for Patients With Spinal Muscular Atrophy Type 1 With One or Two SMN2 Copies Delivering AVXS-101 by Intravenous Infusion
Status: Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 19 Nov 2019
Price : $35 *
At a glance
- Drugs Onasemnogene-abeparvovec (Primary)
- Indications Spinal muscular atrophy
- Focus Registrational; Therapeutic Use
- Acronyms STR1VE EU
- Sponsors AveXis
- 14 Nov 2019 Planned End Date changed from 1 Nov 2020 to 1 Sep 2020.
- 14 Nov 2019 Planned primary completion date changed from 1 Nov 2020 to 1 Sep 2020.
- 26 May 2019 This trial has been discontinued in Spain, according to European Clinical Trials Database.